The short version
- Senior officials are drafting an order to establish a committee that can block NIH grants deemed inconsistent with administration priorities.
- The proposal requires unanimous approval from the new board, including the NIH director and OMB head, altering traditional merit-based review processes.
- Researchers have filed a class-action lawsuit alleging First Amendment violations as billions in health and environmental funding face cuts or freezes.
The Trump administration is moving to establish a new oversight board that would hold veto power over grant awards issued by the National Institutes of Health. This proposed executive order represents a significant shift in how federal biomedical research is funded, placing direct control under White House authority rather than leaving decisions to scientific merit reviews within the agency.
According to reports from multiple outlets, senior officials discussed the initiative during a meeting on Friday. Russell Vought, director of the Office of Management and Budget, along with other administration members, criticized the NIH for supporting projects they characterized as aligned with 'woke' initiatives. These officials argued that current funding practices diverge from the president’s political agenda.
The structure of the proposed board includes both Vought and Jay Bhattacharya, the current NIH director. Decisions regarding grant approvals would require unanimity among board members. This mechanism effectively allows any single member to block funding for specific research proposals, creating a potential bottleneck in the distribution of federal scientific resources.
This approach marks a departure from the agency’s longstanding tradition of evaluating research proposals based on scientific merit and peer review. Bhattacharya has publicly resisted efforts to reduce federal research spending and defended the existing grant-making process during recent discussions. His stance contrasts with Vought’s expressed desire to reshape how federal funds are allocated across executive branch agencies.
The move coincides with a growing legal challenge against the administration’s handling of scientific grants. A class-action lawsuit filed by researchers argues that the government is using its funding power to silence viewpoints it disfavors within the biomedical community. The plaintiffs contend these actions violate First Amendment protections against viewpoint discrimination.
Since the beginning of Trump’s second term, billions of dollars in federal grants related to health, nutrition, environmental protection, and disaster relief have been cut or frozen. Administration officials have flagged research containing keywords such as 'equity,' 'racist,' 'gender,' and 'climate change' for review or termination. These actions suggest a broader strategy to align scientific funding with specific ideological goals.
The Department of Health and Human Services, which oversees the NIH, did not immediately respond to requests for comment regarding the proposed order. The White House also declined to provide immediate clarification on the details of the executive action. This lack of official confirmation leaves the exact scope and implementation timeline of the new board uncertain.
If implemented, the new board could fundamentally alter the landscape of public biomedical research in the United States. As the world’s largest funder of such work, the NIH plays a critical role in advancing medical knowledge and public health initiatives. Shifting control from scientific experts to political appointees raises questions about the future independence of federal research institutions.
The situation highlights ongoing tensions between executive branch priorities and the traditional autonomy of scientific agencies. While the administration argues for accountability and alignment with presidential goals, critics warn that politicizing grant decisions could undermine the integrity of scientific inquiry. The outcome of the pending lawsuit may determine whether these changes can proceed legally.
Observers are closely watching how this development affects ongoing research projects and future funding cycles. The potential for increased scrutiny and ideological filtering of scientific proposals could deter researchers from pursuing certain lines of inquiry. This uncertainty adds another layer of complexity to an already contentious period in federal science policy.
Sources behind this briefing
Go to the original reporting
- The Guardian US↗Trump reportedly to form health funding board that could veto ‘woke’ initiatives
